The International Ph.D. Program for Cell Therapy and Regeneration Medicine (IPCTRM) begin to recruit students for Fall semester in 2017. The mission of this program is to promote translational medicine and clinical trials of cell/stem cell based therapy. Research at IPCTRM provide diverse research fields, including immune cell applications in cancer treatment; blood and mesenchymal stem cells for regenerative processes, wound healing, graft-versus-host disease, and amyotrophic lateral sclerosis; and drug screening platform with cancer stem cells and disease-specific induced pluripotent stem cells. IPCTRM brings experts and scientists together to facilitate outstanding research not only in basic study but also emphasis on clinical translational medicine, and industrial cell/stem cell product development.
ü Cancer immunotherapy
ü Pluripotent small blood stem cells
ü Mesenchymal stem cells
ü Embryonic germ cells and induced pluripotent stem cells
ü Drug screening platform with disease iPS cells
ü FDA/TFDA regulations on cell therapy
ü CMC/Pharm-Tox/Clinical trial/IRB training
Our graduated student is expected to become leader in the following areas:
ü Clinical research coordinator and associate
ü Regulation development and review
ü Research and development
ü Clinical trial drafting and review
ü Academic research
ü Cell manufacturing specialist
Please see the attached 【Flyer】&【Admission Brochure】for more application details.
For more information about program: http://cctrm.tmu.edu.tw/main.php
For information about admissions and scholarships: http://io.tmu.edu.tw/
Further information regarding the program:
Assistant Professor Heng-Yu Chang, Ph.D.
Secretary Janice Huang